Ansun BioPharma
PrivateLast Round
Series B
Oct 14, 2019
Total Funding Raised
$215M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Ansun BioPharma operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series B round in October 2019.
Ansun BioPharma is a biopharmaceutical company that develops host-directed recombinant protein therapeutics to treat severe viral respiratory infections.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Government Contracts, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ansun BioPharma Comparables
Compare Ansun BioPharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Altesa BioSciences | 78% | |
| Synairgen plc | 77% | |
| Cocrystal Pharma Inc | 73% |
For institutional investors. Book with your work email.
Ansun BioPharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Oct 14, 2019 | ||||
| Series A | May 14, 2018 | ||||
| Grant | Sep 1, 2006 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Ansun BioPharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Matrix | Series B, Series A |
| Korea Investment Partners | Series B |
| Bencao Capital | Series B, Series A |
| NIH RADx | Grant |
| Next Capital | Series B |
| Junson Capital | Series B |
| LYFE Capital | Series B, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Monthly visitors increased 89% MoM.
- May 14, 2018
$85M round led by Lilly Asia Ventures
For institutional investors. Book with your work email.
Ansun BioPharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Ansun BioPharma's valuation, stock price, and market status.
Is Ansun BioPharma a public or private company?
Ansun BioPharma is a private company.
What is the current stock price of Ansun BioPharma?
Ansun BioPharma is a private company, so its shares have no public market price. Caplight tracks Ansun BioPharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Ansun BioPharma worth (valuation)?
Valuation information for Ansun BioPharma is not publicly available.
Can I buy Ansun BioPharma stock?
Ansun BioPharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Ansun BioPharma's last funding round?
Ansun BioPharma's most recent funding round was Series B on October 14, 2019.
Who are the main investors in Ansun BioPharma?
Key investors in Ansun BioPharma include Oceanpine Capital, Lilly Asia Ventures, Lilly Asia Ventures.
Will Ansun BioPharma IPO soon?
No public IPO plans have been announced for Ansun BioPharma.
How can I track Ansun BioPharma secondary market activity?
Caplight tracks bids, offers, and trades in Ansun BioPharma's shares on secondary markets.